Ultimovacs ASA Total Debt vs. Book Value Per Share
| ULTI Stock | NOK 1.98 0.05 2.46% |
For Ultimovacs ASA profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ultimovacs ASA to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ultimovacs ASA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ultimovacs ASA's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ultimovacs ASA over time as well as its relative position and ranking within its peers.
Ultimovacs |
Ultimovacs ASA Book Value Per Share vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Ultimovacs ASA's current stock value. Our valuation model uses many indicators to compare Ultimovacs ASA value to that of its competitors to determine the firm's financial worth. Ultimovacs ASA is rated first in total debt category among its peers. It is rated first in book value per share category among its peers . The ratio of Total Debt to Book Value Per Share for Ultimovacs ASA is about 30,522 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ultimovacs ASA's earnings, one of the primary drivers of an investment's value.Ultimovacs Total Debt vs. Competition
Ultimovacs ASA is rated first in total debt category among its peers. Total debt of Biotechnology industry is at this time estimated at about 2.68 Million. Ultimovacs ASA retains roughly 457,000 in total debt claiming about 17% of stocks in Biotechnology industry.
Ultimovacs Book Value Per Share vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Ultimovacs ASA |
| = | 457 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Ultimovacs ASA |
| = | 14.97 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Ultimovacs Book Value Per Share Comparison
Ultimovacs ASA is currently under evaluation in book value per share category among its peers.
Ultimovacs ASA Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Ultimovacs ASA, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Ultimovacs ASA will eventually generate negative long term returns. The profitability progress is the general direction of Ultimovacs ASA's change in net profit over the period of time. It can combine multiple indicators of Ultimovacs ASA, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company was incorporated in 2011 and is headquartered in Oslo, Norway. ULTIMOVACS ASA is traded on Oslo Stock Exchange in Norway.
Ultimovacs Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Ultimovacs ASA. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Ultimovacs ASA position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Ultimovacs ASA's important profitability drivers and their relationship over time.
Use Ultimovacs ASA in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ultimovacs ASA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ultimovacs ASA will appreciate offsetting losses from the drop in the long position's value.Ultimovacs ASA Pair Trading
Ultimovacs ASA Pair Trading Analysis
The ability to find closely correlated positions to Ultimovacs ASA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ultimovacs ASA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ultimovacs ASA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ultimovacs ASA to buy it.
The correlation of Ultimovacs ASA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ultimovacs ASA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ultimovacs ASA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ultimovacs ASA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Ultimovacs ASA position
In addition to having Ultimovacs ASA in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Macroaxis Index Thematic Idea Now
Macroaxis Index
An experimental equal-weighted index theme of selected equities generated based on Macroaxis rating and scoring system. The Macroaxis Index theme has 52 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Index Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Ultimovacs Stock
To fully project Ultimovacs ASA's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Ultimovacs ASA at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Ultimovacs ASA's income statement, its balance sheet, and the statement of cash flows.